CClinicalTrials.gg
Active, not recruitingNCT03308929Updated Jun 15, 2025

Prospective G7 Dual Mobility Total Hip PMCF

An observational study in Clinical Outcomes, Functional Outcomes and Radiological Outcomes, sponsored by Zimmer Biomet. Active, not recruiting at 6 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-06-15.

Sponsored by Zimmer Biomet · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a prospective multi-center clinical evaluation following recipients of the G7 Dual Mobility hip device. The primary objective is to characterize survivorship of the G7 hip at five years post-index procedure. Secondary objectives include documentation of clinical outcomes, safety and radiographic data.

Read the detailed description

This multi-center prospective follow-up study will evaluate clinical outcomes, functional outcomes, radiological outcomes and further characterize the safety profile of the G7 Dual Mobility Hip Arthroplasty System. This will be accomplished by assessing these domains using the Harris Hip Score, UCLA Activity Score, and EQ-5D-3L, obtaining and assessing radiographs and the tracking of device or procedure related adverse events. Subjects will undergo unilateral primary or revision total hip arthroplasty and will then be followed for 10 years with intervals at 6 weeks, 1-, 2-, 3- 5- and 10 years. For the 10 year visit, subjects will not be required to present in their doctor's office, but will fill out a survey. Subsequent to 10 year data collection, the subject's participation in the study will be compete.

02

Conditions studied

  • Clinical Outcomes
  • Functional Outcomes
  • Radiological Outcomes
  • Survivorship
  • Safety
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients undergoing revision hip arthroplasty, undergoing a hip arthroplasty to correct a functional deformity, patients seeking treatment for femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques, and patients with significant hip pain or functional limitations and who are at a high dislocation risk will be considered for the study. Patients may have avascular necrosis, osteo- or rheumatoid arthritis.

Inclusion criteria

  • Patients who are undergoing revision hip arthroplasty

    -OR

  • Patients who are undergoing total hip arthroplasty (THA) for the correction of a functional deformity

    • OR
  • Patients in need of treatment of femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques

    • OR
  • Patients suffer from substantial pain and/or limited function, are appropriate for a primary total hip arthroplasty, considered at high risk for dislocation and have one of the following:

    • Non-inflammatory degenerative joint disease, including osteoarthritis and avascular necrosis
    • Rheumatoid arthritis
  • Decision to have a G7 Dual Mobility system implanted was made independently and prior to recruitment into study
  • From 18 to 80 years of age (inclusive) at time of procedure
  • BMI equal to or less than 35
  • Unilateral total hip replacement
  • Willing and able to comply with the study procedures

Exclusion criteria

Exclusion Criteria:

  • Patients undergoing total hip arthroplasty following non-union of previous surgically treated fracture.
  • Infection, sepsis or osteomyelitis at the affected joint
  • Significant osteoporosis as defined by treating surgeon
  • Metabolic disorders which may impair bone formation
  • Osteomalacia
  • Distant foci of infections which may spread to the implant site
  • Rapid joint destruction, marked bone loss or bone resorption on preoperative radiographs
  • Underwent contralateral THA within 12 months of planned index procedure
  • Contralateral THA planned within 12 months of index procedure
  • Vascular insufficiency, muscular atrophy at the implant site or neuromuscular disease
  • The patient is

    • A prisoner
    • A known alcohol or drug abuser
  • The patient has any concomitant disease which is likely to jeopardize the functioning or success of the implant
  • The patient is known to be pregnant
  • The patient has a known sensitivity or allergy to one or more of the implanted materials, inducing but not limited to chromium, cobalt, and ceramic
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Interventions

  • DeviceG7 Dual Mobility hip

    Total hip arthroplasty and implantation of the G7 device

05

What researchers measure

Primary outcomes

  1. Survivorship of the study device

    This is assessed by removal of the study device from the patient for any reason, including failure of the device, infection, or traumatic injury.

    Time frame: 5 years

Secondary outcomes

  1. Radiographic measurements of the implanted device

    Standard AP radiographs of implanted hip will assess the positioning of the device as well as lucencies and other potential anomalies.

    Time frame: 10 years

  2. Frequency and incidence of adverse events for all subjects with particular focus on those related or potentially related to the device

    Assessed by tracking the type of adverse event, severity and relation of the event(s) to the study device

    Time frame: 10 years

  3. Patient Physical Activity

    UCLA activity score - patient self assessment

    Time frame: 10 years

  4. Patient Quality of Life

    EQ-3L-5D quality of life measure - patient self assessment

    Time frame: 10 years

  5. Harris Hip Score

    Harris Hip score measures pain, function, absence of deformity, and range of motion. Scores range from 0-100 with higher scores representing less dysfunction and better outcomes

    Time frame: 10 years

06

Study locations

6 sites
  • Jersey City Medical Center
    Jersey City, New Jersey 07302, United States
  • New Mexico Orthopaedics
    Albuquerque, New Mexico 87106, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Tidewater Orthopaedics
    Hampton, Virginia 23666, United States
  • Ortho Virginia
    Richmond, Virginia 23235, United States
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03308929
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Oct 13, 2017
Start date
Feb 28, 2017
Primary completion
Jul 1, 2027 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Jun 15, 2025

Study contacts

Hillary Overholser, MS
study director · Zimmer Biomet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion